Abivertinib maleate - ACEA Biosciences

Drug Profile

Abivertinib maleate - ACEA Biosciences

Alternative Names: A 610MA; AC 0100; AC 0100 Maleate; AC-0010MA; ACEA100610MA; EX-ACEA0010MA

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ACEA Biosciences
  • Developer ACEA Biosciences; Hangzhou ACEA Pharmaceutical Research
  • Class Antineoplastics; Heterocyclic compounds; Pyrimidines; Pyrroles
  • Mechanism of Action Apoptosis stimulants; Epidermal growth factor receptor antagonists; Mitogen-activated protein kinase inhibitors; Raf kinase inhibitors; Ras protein inhibitors; Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer
  • Phase I B cell lymphoma
  • No development reported Lung cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lung-cancer in China (PO, Capsule)
  • 01 Sep 2017 Hangzhou ACEA Pharmaceutical Research completes a phase I trial in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT03001609)
  • 28 Feb 2017 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater) in China (PO) (NCT03060850)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top